title: Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.
abstract: Entecavir is an oral antiviral drug with selective activity against hepatitis B virus (HBV). We conducted a randomized, placebo-controlled, dose-escalating study in patients with chronic hepatitis B infection in which we evaluated the efficacy and safety of entecavir given for 28 days. Follow-up was 24 weeks. All doses of entecavir (0.05 mg, 0.1 mg, 0.5 mg, and 1.0 mg) showed a pronounced suppression of replication of the HBV with a 2.21, 2.29, 2.81, and 2.55 mean log(10) reduction of viral load, respectively. Approximately 25% of patients on entecavir showed a decline of HBV DNA below the limit of detection of the Chiron HBV-DNA assay (<0.7 MEq/mL). In the postdosing follow-up period patients who were treated with 0.5 and 1.0 mg of entecavir showed a considerably slower return in their HBV DNA levels to baseline compared with those patients treated with lower dosages (P <.05). All doses of entecavir were well tolerated with no significant difference between treated patients and those receiving placebo. No significant changes in alanine transaminase (ALT) levels within the dose groups and the placebo group between baseline and the end of treatment were observed. Three patients (9%) (1 each in the 0.05-, 0.1-, and 0.5-mg groups) experienced asymptomatic hepatitis flares 16 weeks (2 patients) and 24 weeks (1 patient) after withdrawal of entecavir. In conclusion, in this 28-day study of entecavir a pronounced decrease of HBV DNA was observed and there were no significant side effects in entecavir patients in comparison with placebo-treated patients.
authors.affiliation: Erasmus University Hospital, Rotterdam, The Netherlands. deman@mdl.azr.nl
authors.forename: R A
authors.initials: RA
authors.lastname: de Man
authors.forename: L M
authors.initials: LM
authors.lastname: Wolters
authors.forename: F
authors.initials: F
authors.lastname: Nevens
authors.forename: D
authors.initials: D
authors.lastname: Chua
authors.forename: M
authors.initials: M
authors.lastname: Sherman
authors.forename: C L
authors.initials: CL
authors.lastname: Lai
authors.forename: A
authors.initials: A
authors.lastname: Gadano
authors.forename: Y
authors.initials: Y
authors.lastname: Lee
authors.forename: F
authors.initials: F
authors.lastname: Mazzotta
authors.forename: N
authors.initials: N
authors.lastname: Thomas
authors.forename: D
authors.initials: D
authors.lastname: DeHertogh
mesh_terms: D000284:Administration, Oral; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004279:DNA, Viral / Q000032:analysis; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D006147:Guanine / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006515:Hepatitis B virus / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008099:Liver / Q000201:enzymology; D012449:Safety; D000637:Transaminases / Q000378:metabolism
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; C413685:entecavir; D006147:Guanine; D000637:Transaminases